Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cyclopentanone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.62 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cycloheptanone SCHEMBL3602798 | 0.97 | TRIM24 (0.65) | TRIM24TRIM33ALDH1A1FFAR3LCK | |
| Cyclohexanone SCHEMBL28536813 | 0.97 | TRIM24 (0.65) | TRIM24TRIM33ALDH1A1FFAR3LCK | |
| Cyclohexanone SCHEMBL9421237 | 0.97 | TRIM24 (0.65) | TRIM24TRIM33ALDH1A1FFAR3LCK | |
| Cyclohexanone SCHEMBL3600071 | 0.97 | TRIM24 (0.65) | TRIM24TRIM33ALDH1A1FFAR3LCK | |
| Cyclohexanone SCHEMBL28259728 | 0.94 | TRIM24 (0.61) | TRIM24TRIM33ALDH1A1FFAR3LCK | |
| Cyclohexanone SCHEMBL2255977 | 0.92 | ALDH1A1 (0.58) | TRIM24TRIM33ALDH1A1FFAR3LCK | |
| Cyclopentanone SCHEMBL8150513 | 0.90 | TRIM24 (0.67) | TRIM24TRIM33ALDH1A1THRBCA1 | |
| Acetic Acid SCHEMBL27911516 | 0.90 | — | — | |
| Butanedione SCHEMBL15658503 | 0.88 | TRIM24 (0.62) | TRIM24TRIM33ALDH1A1THRBCA1 | |
| Cyclohexanone SCHEMBL1071504 | 0.88 | TRIM24 (0.69) | TRIM24TRIM33ALDH1A1THRBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118922189-A | Novel prodrugs derived from niacin and ribose | 线粒体能量有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-111349018-B | Process for fluorinating inorganic or organic compounds by direct fluorination | 福建永晶科技股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11795138-B2 | Process of fluorinating inorganic compounds by direct fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2023-10-24 | — | — | US | disclosed |
| US-20220135516-A1 | Process of Fluorinating Inorganic Compounds by Direct Fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20210053911-A1 | Process of Fluorinating Inorganic or Organic Compounds by Direct Fluorination | FUJIAN YONGJING TECHNOLOGY CO., LTD (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3782969-A1 | PROCESS OF FLUORINATING INORGANIC OR ORGANIC COMPOUNDS BY DIRECT FLUORINATION | Fujian Yongjing Technology Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| CN-111349018-A | Process for fluorinating inorganic or organic compounds by direct fluorination | 福建永晶科技股份有限公司 | 2020-06-30 | — | — | CN | disclosed |
| CN-103140505-B | Resin particle and method for producing same, anti-glare film, light-diffusing resin composition, and external preparation | 积水化成品工业株式会社 | 2017-06-30 | — | — | CN | disclosed |
| CN-106414689-A | Perfume composition | 奇华顿股份有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-105209446-A | GPR120 agonists for the treatment of type ii diabetes | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| CN-100594040-C | Implants comprising functional carbon coatings | BLUE MEMBRANES GMBH | 2010-03-17 | — | — | CN | disclosed |
| EP-1748982-B1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2009-07-29 | — | — | EP | disclosed |
| CN-100384490-C | Medical implants comprising biocompatible coatings | BLUE MEMBRANES GMBH (DE) | 2008-04-30 | — | — | CN | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| EP-1748982-A1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005108362-A1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795138-B2 | Process of fluorinating inorganic compounds by direct fluorination | AFF2, CYP4F2, AFF1 | TRIM24 3607/4885TRIM33 2928/4885ALDH1A1 1237/4885 |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | APP, BACE1, CHAT | TRIM24 2487/4885TRIM33 3712/4885ALDH1A1 88/4885 |
| US-20210053911-A1 | Process of Fluorinating Inorganic or Organic Compounds by Direct Fluorination | CYP4F2, AFF2, CYP4F3 | TRIM24 3323/4885TRIM33 2627/4885ALDH1A1 897/4885 |
| US-20220135516-A1 | Process of Fluorinating Inorganic Compounds by Direct Fluorination | AFF2, CYP4F2, AFF1 | TRIM24 3607/4885TRIM33 2928/4885ALDH1A1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.